JPWO2023141247A5 - - Google Patents
Info
- Publication number
- JPWO2023141247A5 JPWO2023141247A5 JP2024543083A JP2024543083A JPWO2023141247A5 JP WO2023141247 A5 JPWO2023141247 A5 JP WO2023141247A5 JP 2024543083 A JP2024543083 A JP 2024543083A JP 2024543083 A JP2024543083 A JP 2024543083A JP WO2023141247 A5 JPWO2023141247 A5 JP WO2023141247A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- nucleotides
- rnai oligonucleotide
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263301454P | 2022-01-20 | 2022-01-20 | |
| US63/301,454 | 2022-01-20 | ||
| US202263328629P | 2022-04-07 | 2022-04-07 | |
| US63/328,629 | 2022-04-07 | ||
| PCT/US2023/011200 WO2023141247A2 (en) | 2022-01-20 | 2023-01-20 | Compositions and methods for inhibiting complement factor b |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025503034A JP2025503034A (ja) | 2025-01-30 |
| JPWO2023141247A5 true JPWO2023141247A5 (https=) | 2026-01-27 |
| JP2025503034A5 JP2025503034A5 (https=) | 2026-01-27 |
Family
ID=87349101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543083A Pending JP2025503034A (ja) | 2022-01-20 | 2023-01-20 | 補体因子ｂを阻害するための組成物及び方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250327070A1 (https=) |
| EP (1) | EP4465996A2 (https=) |
| JP (1) | JP2025503034A (https=) |
| KR (1) | KR20240135650A (https=) |
| AU (1) | AU2023208539A1 (https=) |
| CA (1) | CA3247136A1 (https=) |
| CL (1) | CL2024002156A1 (https=) |
| CO (1) | CO2024011199A2 (https=) |
| CR (1) | CR20240346A (https=) |
| DO (1) | DOP2024000140A (https=) |
| IL (1) | IL314240A (https=) |
| MX (1) | MX2024009019A (https=) |
| PE (1) | PE20250156A1 (https=) |
| TW (1) | TW202345866A (https=) |
| UY (1) | UY40118A (https=) |
| WO (1) | WO2023141247A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025026228A1 (zh) * | 2023-07-28 | 2025-02-06 | 苏州炫景生物科技有限公司 | Cfb抑制剂组合物及其应用 |
| WO2025113592A1 (zh) * | 2023-12-01 | 2025-06-05 | 厦门甘宝利生物医药有限公司 | 一种抑制补体系统基因表达的rna抑制剂及其应用 |
| WO2025140402A1 (zh) * | 2023-12-28 | 2025-07-03 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2025151250A2 (en) * | 2024-01-09 | 2025-07-17 | Adarx Pharmaceuticals, Inc. | Complement factor b-modulating compositions and methods of use thereof |
| US20250382616A1 (en) * | 2024-06-18 | 2025-12-18 | Sanegene Bio Usa Inc. | Small interfering rna targeting cfb and uses thereof |
| WO2026046277A1 (zh) * | 2024-08-28 | 2026-03-05 | 倍臻生物技术（苏州）有限公司 | 用于抑制补体因子b(cfb)基因表达的双链核糖核酸及其缀合体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201804960RA (en) * | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| MX2022013606A (es) * | 2020-04-30 | 2023-01-16 | Alnylam Pharmaceuticals Inc | Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas. |
-
2023
- 2023-01-19 TW TW112102833A patent/TW202345866A/zh unknown
- 2023-01-19 UY UY0001040118A patent/UY40118A/es unknown
- 2023-01-20 KR KR1020247027278A patent/KR20240135650A/ko active Pending
- 2023-01-20 CA CA3247136A patent/CA3247136A1/en active Pending
- 2023-01-20 IL IL314240A patent/IL314240A/en unknown
- 2023-01-20 JP JP2024543083A patent/JP2025503034A/ja active Pending
- 2023-01-20 PE PE2024001648A patent/PE20250156A1/es unknown
- 2023-01-20 CR CR20240346A patent/CR20240346A/es unknown
- 2023-01-20 AU AU2023208539A patent/AU2023208539A1/en active Pending
- 2023-01-20 WO PCT/US2023/011200 patent/WO2023141247A2/en not_active Ceased
- 2023-01-20 EP EP23743749.6A patent/EP4465996A2/en active Pending
- 2023-01-20 US US18/292,187 patent/US20250327070A1/en active Pending
-
2024
- 2024-07-18 DO DO2024000140A patent/DOP2024000140A/es unknown
- 2024-07-18 CL CL2024002156A patent/CL2024002156A1/es unknown
- 2024-07-19 MX MX2024009019A patent/MX2024009019A/es unknown
- 2024-09-05 CO CONC2024/0011199A patent/CO2024011199A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025118886A (ja) | 筋疾患治療用医薬組成物 | |
| US20230203498A1 (en) | Single-stranded oligonucleotide | |
| AU2020203825A1 (en) | Antisense-induced exon2 inclusion in acid alpha-glucosidase | |
| JP2021006029A5 (https=) | ||
| JP2022069529A (ja) | 血液脳関門通過型ヘテロ２本鎖核酸 | |
| JP2019214587A5 (https=) | ||
| EP4389891A1 (en) | Modified heteronucleic acid containing morpholino nucleic acid | |
| JP2022527108A (ja) | Ｋｒａｓ関連疾患または障害の治療のための組成物及び方法 | |
| JP2003513887A (ja) | オリゴヌクレオチドｎ３’→ｐ５’チオホスホルアミデート：それらの合成および使用 | |
| JPH10510433A (ja) | 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド | |
| JP7724259B2 (ja) | 新規のチオホスホラミダイト | |
| JP2020529197A5 (https=) | ||
| JP2025503034A (ja) | 補体因子ｂを阻害するための組成物及び方法 | |
| WO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| JPWO2021222549A5 (https=) | ||
| JP2021515784A (ja) | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 | |
| KR20200104347A (ko) | 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드 | |
| TW202342748A (zh) | Mapt rna干擾劑 | |
| KR20230173116A (ko) | 보체 성분 3 발현을 저해하기 위한 조성물 및 방법 | |
| JPWO2023141247A5 (https=) | ||
| EP4123023A1 (en) | Heteronucleic acid containing morpholino nucleic acid | |
| CN115927337A (zh) | 一种siRNA及其缀合物 | |
| WO2025067351A2 (en) | Novel sirna constructs, therapeutics, and modifications | |
| JPWO2022226127A5 (https=) | ||
| CN102028947B (zh) | Fam3b基因的抑制剂和组合物及抑制方法以及脂肪肝的疗法和抑制剂的制药用途 |